Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

About this update from Dyne Therapeutics, Inc.

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44 th  Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors & Media section of Dyne’s website at  https://investors.dyne-tx.com/news-and-events/events-and-presentations  and a replay will be accessible for 30 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/ , and follow us on  X , LinkedIn  and  Facebook .   Contacts: Investors Mia Tobias [email protected] 781-317-0353 Media Stacy Nartker  [email protected] 781-317-1938

View stock analysis, news, and events for Dyne Therapeutics, Inc.